India Clinical Trials Market to Grow with a CAGR of 8.64% through 2030
Adoption of new technology in clinical research and increasing research & development promoting outsourcing is expected to drive the India Clinical Trials Market growth in the forecast period.
According to TechSci Research report, “India Clinical
Trials Market- By Region, Competition, Forecast &
Opportunities, 2030F”, the India Clinical Trials Market stood at USD 2.05 Billion in 2024 and is
anticipated to grow with a CAGR of 8.64% through 2030. India Clinical Trials Market is driven by numerous factors, making it an
attractive destination for pharmaceutical companies and researchers. India's
vast and diverse patient population provides a broad base for clinical trials,
facilitating quicker participant enrolment. The cost-effectiveness of
conducting trials in India, due to lower operational and labor costs, attracts
global companies.
The presence of a large pool of skilled medical
professionals and the increasing government support in streamlining regulations
also contribute to the market growth. The growing prevalence of lifestyle
diseases in India necessitates the development and testing of new treatment methods,
further propelling the clinical trials market.
India Clinical Trials Market, a vital and integral
aspect of the healthcare ecosystem, has witnessed remarkable growth and
diversification in recent years. This upward trend can be attributed to various
factors. India's rich demographic diversity and vast patient pool make
it an attractive destination for conducting clinical trials. The
cost-effectiveness offered by India further enhances its appeal to global
pharmaceutical companies and research organizations. The 2019 amendments to the
New Drugs and Clinical Trials (NDCT) Rules have significantly contributed to
the market's expansion. These amendments have streamlined the approval
processes, introduced compensation provisions, and allowed for concurrent phase
I and phase II trials. As a result, companies specializing in therapeutic areas
such as oncology, cardiovascular diseases, and diabetes have increasingly
chosen India as a preferred location for their clinical trials. This trend
aligns with the global prevalence of these diseases and underscores India's
potential as a key player in advancing medical research and innovation.
The presence of Contract Research Organizations (CROs)
has played a pivotal role in supporting the growth of the clinical trials
industry in India. These organizations offer a comprehensive range of services,
including site selection, patient recruitment, data management, and statistical
analysis. By providing these services, CROs have made the clinical trials
process more efficient and manageable for pharmaceutical companies, thereby
contributing to the overall development of the market.
It is crucial to address certain challenges
in order to sustain and further enhance the growth of the India Clinical Trials
Market. Ethical concerns regarding informed consent and patient safety must be
given utmost importance. Striking a balance between encouraging clinical trials
and ensuring stringent regulations to protect vulnerable patient groups is of
paramount significance. Infrastructure and skill deficits in
certain regions of the country pose significant hurdles that need to be
addressed through strategic investments and capacity building initiatives.
Looking ahead, the India Clinical Trials Market is
poised for robust growth. The advent of novel technologies such as virtual and
decentralized trials, artificial intelligence (AI), and real-world data has the
potential to reshape the landscape of clinical trials in India. The COVID-19 pandemic has highlighted the importance of rapid clinical research
and development, setting the stage for a more streamlined and efficient
clinical trials market in the future. With deliberate and strategic policies,
India can harness this potential and emerge as a global hub for clinical
trials, making significant contributions to global healthcare progress and
innovation.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Clinical Trials Market”
India Clinical Trials Market is segmented into phase,
study design, indication, regional distribution, and company.
Based on indication, the Oncology sector in India is
on the brink of experiencing a substantial surge in the Clinical Trials Market.
This growth can be attributed to the alarming rise in cancer prevalence across
the country, which has created an urgent need for innovative therapies and
breakthrough treatments. The ongoing advancements in cancer research, coupled
with the pressing demand for effective clinical trials, are paving the way for
significant expansion in the Indian Clinical Trials Market. The expansion of
this market not only holds the potential for groundbreaking discoveries but
also promises remarkable advancements in the fight against cancer. With the
increasing focus on precision medicine and personalized treatments, the demand
for clinical trials in India is expected to skyrocket. This presents an
opportunity for both domestic and international pharmaceutical companies to
collaborate with Indian research institutions and tap into the vast patient
population.
The Indian government's initiatives to
streamline the regulatory framework and provide incentives for conducting
clinical trials have further fueled the growth of this market. The improved
regulatory environment coupled with a large pool of experienced healthcare
professionals and state-of-the-art infrastructure has positioned India as a
preferred destination for conducting oncology clinical trials. The expansion of
the Indian Clinical Trials Market not only brings hope to countless individuals
and families affected by cancer but also contributes to the overall progress in
the field of oncology. It enables researchers to explore novel treatment approaches,
validate the efficacy of new drugs, and ultimately improve patient outcomes.
The collective efforts of healthcare professionals, researchers, and industry
stakeholders in India are driving the advancements in cancer care and shaping a
brighter future for oncology patients. The Oncology sector in India is
witnessing a surge in the Clinical Trials Market due to the rising cancer
prevalence and the need for innovative therapies. This expansion not only
presents opportunities for groundbreaking discoveries but also contributes to
the fight against cancer, bringing hope and progress to countless individuals
and families affected by this devastating disease.
Based on region, western India is currently leading
the way in the Clinical Trials Market in India, due to a multitude of
contributing factors. One of the key reasons for its dominance is the presence
of major pharmaceutical companies and renowned research institutions in the
region. This creates a highly conducive environment for conducting clinical
trials, fostering a thriving ecosystem that encourages innovation and
collaboration. Western India boasts a well-established healthcare
infrastructure that supports the seamless execution of various phases of
clinical trials. This infrastructure, combined with a large and diverse patient
pool, provides ample opportunities for researchers and scientists to carry out
comprehensive and robust studies. The availability of such a diverse patient
population allows for a better understanding of the effectiveness and safety of
new treatments.
The supportive government policies in
these states play a crucial role in attracting global pharmaceutical companies
to conduct trials in Western India. These policies not only provide incentives
but also create a favorable regulatory environment that facilitates the smooth
progress of clinical research. As a result, Western India has emerged as a
preferred destination for conducting clinical trials, making significant
contributions to the advancement of medical science and the development of new
therapies. Western India's dominance in the Clinical Trials Market is a result
of the region's strong presence of pharmaceutical companies and research
institutions, well-established healthcare infrastructure, diverse patient pool,
and supportive government policies. These factors collectively contribute to
creating an environment that fosters innovation, collaboration, and the
successful execution of clinical trials.
Major companies operating in India Clinical Trials
Market are:
- IQVIA RDS (India) Private Limited
- PAREXEL International (India) Private Ltd
- Icon Clinical Research India Pvt Ltd
- Veeda Clinical Research Limited
- Aragen Life Sciences Ltd.
- Abiogenesis Clinpharm Pvt Ltd
- Cliantha Research Limited
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The future
trajectory of the clinical trials market in India promises substantial growth,
propelled by a convergence of factors that underscore the country's potential
as a preferred destination for clinical research endeavors. Foremost among
these factors is India's extensive and diverse patient population, presenting a
vast reservoir of individuals across different demographics and disease
profiles. This diversity not only enhances the inclusivity and generalizability
of clinical trial data but also facilitates the evaluation of treatments across
varied patient cohorts, offering valuable insights for global drug development
programs. India's robust clinical infrastructure, characterized by
state-of-the-art medical facilities, specialized research centers, and
well-equipped hospitals, positions the country as a conducive environment for
conducting clinical trials. Coupled with a cadre of well-qualified
investigators and medical professionals adept at adhering to international
standards and protocols, India offers a conducive ecosystem for conducting
high-quality research studies across therapeutic areas. In addition to its clinical
capabilities, India's attractiveness as a clinical trial destination is
bolstered by its cost-effectiveness compared to Western counterparts. The
relatively lower operational costs, coupled with competitive patient
recruitment and retention rates, make India an economically viable option for
sponsors and CROs seeking to optimize trial budgets without compromising on
quality or efficiency.,” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“India Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of India Clinical Trials Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Clinical Trials Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com